In a phase II trial, patients with CRC were administered subcutaneous injection of granulocyte-macrophage colony-stimulating factor and low-dose IL-2 following chemotherapy with gemcitabine plus FOLFOX-4 (oxaliplatin, fluorouracil, and folic acid). Here, CSF2 is linked to colorectal carcinoma.